The 13-year long-term follow-up on the effectiveness and immunogenicity of the quadrivalent human papillomavirus vaccine in Chinese females vaccinated at 20-45 years of age.

Hum Vaccin Immunother

Department of Epidemiology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.

Published: December 2024

The LTFU study was registered at the Chinese Clinical Trial Registry, ChiCTR2100052313.

Download full-text PDF	Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11486006	PMC
http://dx.doi.org/10.1080/21645515.2024.2412391	DOI Listing

Publication Analysis

13-year long-term

long-term follow-up

follow-up effectiveness

effectiveness immunogenicity

immunogenicity quadrivalent

quadrivalent human

human papillomavirus

papillomavirus vaccine

vaccine chinese

chinese females

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!